Alyeska Investment Group
VTAE

Alyeska Investment Group’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Alyeska Investment Group’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-375,000
Closed -$2.49M – 542
2016
Q1 		$2.49M Buy
+375,000
New +$3.41M 0.02% 315
2015
Q4 		– Sell
-45,631
Closed -$502K – 538
2015
Q3 		$502K Buy
45,631
+8,590
+23% +$91.3K 0.01% 425
2015
Q2 		$533K Buy
37,041
+600
+2% +$8.15K 0.01% 449
2015
Q1 		$427K Buy
+36,441
New +$492K 0.01% 474
2014
Q4 		– Sell
-182,609
Closed -$1.39M – 579
2014
Q3 		$1.39M Buy
+182,609
New +$1.42M 0.03% 308

Other funds holding VTAE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group's VTAE Position: Q2 2016 in Review

Alyeska Investment Group sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q2 2016, closing a stake of 375,000 shares — an estimated $2.49M sold.

Alyeska Investment Group first reported a position in VTAE in Q3 2014 and held it in 5 quarters. The position peaked at $2.49M in Q1 2016. 71 funds tracked by Wall St. Rank hold VTAE as of Q2 2016.

  • Alyeska Investment Group reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q2 2016 after selling out during the quarter.
  • Alyeska Investment Group sold 375,000 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q2 2016, an estimated $2.49M.
  • Alyeska Investment Group first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2014 and held it in 5 quarters.
  • Alyeska Investment Group's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $2.49M in Q1 2016.
  • 71 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q2 2016.

Based on Alyeska Investment Group's 13F filing for Q2 2016, filed 15 Aug 2016.